![]() Share includes the impact of a pre-tax charge in the amount of $110 million for the period to reflect a one-time payment that the company now expects to make to Impax per the terms of Endos 2010 settlement and license agreement with Impax. Services and execute our long-term vision of providing our customers with innovative healthcare solutions. We are keenly focused on execution that creates the opportunity for us to continue to grow our products and Temporary, constraints to supplies of some of our key pharmaceutical products, said Dave Holveck, president and CEO of Endo. Im extremely proud of the response by the organization in resolving the challenging, but Adjusted diluted earnings per share for first quarter 2012 were $0.87, down (Impax).Īdditionally, adjusted net income for the three months ended March 31, 2012, was $106 million, down 12 percent, compared with $120 million in the same period in 2011. The 2012 net loss was primarily driven by a one-time charge related to a first quarter 2012 accrual stemming from a 2010 litigation settlement with Impax Laboratories Inc. 31, 2012 of $87 million or $0.75 reported diluted loss per share, compared with net income of $56 million reported in theĬomparable 2011 period or $0.46 reported diluted earnings Endo incurred a net loss for the three months ended Mar. Of 2011, reflecting organic growth and the acquisition of AMS. Total revenues during the first quarter of 2012 increased 23 percent to $691 million, compared with $560 million in the same quarter OPANA ER and Voltaren Gel now in steady supply Resolving temporary supply disruption announced in early January.ĬHADDS FORD, Pa., May 1, 2012 Endo (Nasdaq: ENDP) today reported financial results for the first quarter Management expects return to year-over-year adjusted diluted earnings growth for remainder of 2012. Reported quarterly diluted loss per share of $0.75 versus earnings per share of $0.46 for prior year. Total quarterly revenues of $691 million, increased 23 percent versus prior year Driven by full quarter addition of AMS as well asĪdjusted diluted EPS of $0.87, aligned with prior guidance of below $0.90. fell 39 cents to $34.75 in afternoon trading, while the Nasdaq exchange climbed 1 percent.ENDO REPORTS FIRST QUARTER FINANCIAL RESULTS ANDĪNNOUNCES RETURN TO STEADY SUPPLY OF OPANA® ER AND Shares of Endo Pharmaceuticals Holdings Inc. Analysts expect, on average, earnings of $5.11 per share. The company expects adjusted earnings of between $5 and $5.20 for the year, the same forecast it made in February. Sales for Endo’s Lidoderm pain patch climbed 11 percent to $210 million in the quarter. It recorded no sales for Voltaren Gel and $81 million in sales for Opana ER, down 4 percent from last year’s quarter.Įndo said it has since returned to a steady supply of both products and expects their sales to return to growth for the remainder of 2012. The company suspended sales of Opana ER and its joint pain treatment Voltaren Gel due to manufacturing problems at a Lincoln, Neb., factory that made the products. Sales of Endo’s branded pharmaceuticals fell 3 percent in the first quarter to about $364 million. The company’s revenue jumped due in part to its $2.9-billion purchase of American Medical Systems Inc., which makes devices and treatments for use in urology and gynecology. Revenue climbed 23 percent to $690.6 million.Īnalysts surveyed by FactSet expected, on average, earnings of 87 cents per share on $700.1 million in revenue.Įndo made the Impax payment as part of the settlement of a patent dispute over generic versions of Endo’s pain drug Opana ER. Adjusted earnings, which do not count the charge, came in at 87 cents per share. ![]() That compares to earnings of $55.8 million, or 46 cents per share, in last year’s first quarter. Endo Pharmaceuticals turned a first-quarter loss after absorbing a $110-million pre-tax charge connected to a settlement and license agreement with Impax Laboratories Inc.Įndo, based in Chadds Ford, Pa., said Tuesday it lost $87.3 million, or 75 cents per share, in the three months that ended March 31. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |